KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Sarepta Therapeutics (SRPT) over the last 14 years, with Q3 2025 value amounting to $36.3 million.

  • Sarepta Therapeutics' Other Non-Current Liabilities fell 2341.77% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year decrease of 2341.77%. This contributed to the annual value of $47.4 million for FY2024, which is 2440.94% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Other Non-Current Liabilities stood at $36.3 million, which was down 2341.77% from $47.4 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Other Non-Current Liabilities registered a high of $50.8 million during Q1 2021, and its lowest value of $36.1 million during Q2 2023.
  • For the 5-year period, Sarepta Therapeutics' Other Non-Current Liabilities averaged around $43.2 million, with its median value being $43.6 million (2021).
  • In the last 5 years, Sarepta Therapeutics' Other Non-Current Liabilities soared by 39570.65% in 2021 and then crashed by 2341.77% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Other Non-Current Liabilities (Quarter) stood at $43.6 million in 2021, then dropped by 15.37% to $36.9 million in 2022, then grew by 3.25% to $38.1 million in 2023, then increased by 24.41% to $47.4 million in 2024, then fell by 23.42% to $36.3 million in 2025.
  • Its last three reported values are $36.3 million in Q3 2025, $47.4 million for Q2 2025, and $47.4 million during Q1 2025.